Showing 2 results for Ehsani, MD
Nafiseh Esmaeili, Md, Zahra Halaji, Md, Amirhooshang Ehsani, Md, Mahboubeh Eghbalian, Md, Abbas Karimi,
Volume 4, Issue 2 (6-2013)
Abstract
Background and Aim: Alopecia Areata is a chronic inflammatory disease which involves hair follicles. The aim of this study was to assess the efficacy of oral sulfasalazine in the treatment of recalcitrant alopecia areata.
Methods: Patients with refractory alopecia areata who were eligible for the study, after providing informed consent were treated with oral sulfasalazine for 6 months. After completion of treatment, regrowth of vellus and terminal hairs were determined based on clinical examination and comparing the new photographs with the baseline ones.
Results: Sixteen patients were enrolled in the present study but only 5 patients completed it. No response was seen in 3 patients. After 4 months, 55-60% response to treatment was observed in 1 patient, but the disease relapsed at the end of fourth month. In 1 patient, 15% hair regrowth was observed but treatment was discontinued after the second month due to side effects. Side effects were observed in 2 patients.
Conclusion: Since only refractory alopecia areata patients had been enrolled to the study, the results could not be generalized to all patients with alopecia areata. Therapeutic response in the patients with alopecia areata is disappointing and any poor treatment response or failure of treatment in refractory cases of the disease cannot rule out the efficacy of the drug in the milder forms of the alopecia areata.
Amiirhooshang Ehsani, Md, Pedram Noormohammadpour, Md, Asieh Shakib, Fatemeh Gholamali, Md,
Volume 4, Issue 2 (6-2013)
Abstract
Background and Aim: Xanthelasma is a benign condition considered which is mainly as a cosmetic problem. There are many destructive treatment options that may result in scar formation and dyspigmentation such as cryotherapy and electro-cauthery. According to these side effects finding a non-invasive solution could be important. At this study we aimed to evaluate the effect of PDL laser in the treatment xanthalasma.
Methods: Patients with bilateral palpebral xanthelasma having normal serum lipid profile were eligible for the study if they had no history of a collagen vascular disease or dermatologic disorders that were associated with Koebner phenomenon. All patients had two separate pulsed dye laser (PDL) treatment sessions, with a four-week gap in between and were photographed before every laser treatment session and four weeks after the second session. Visual analogue scale (VAS) scoring system was used to determine effect of treatment by two academic dermatologists blinded to the study as the referees. Mean healing score by the two referees considered as final score.
Results: Nine patients with a mean age (±standard deviation) of 38.0 (±9.2) years were included. All patients were female. The commonest site of lesions was upper lid, and final resolution score for all patients was less than 25%. There were no significant differences between viewpoints of the two referees. There were no major post operative complications. Patients followed for six months after the end of the treatment and there was no adverse effect.
Conclusion: The present study failed to demonstrate therapeutic efficacy of PDL in the treatment of xanthelasma. PDL with limited session numbers could not be considered as an alternative treatment for xanthelasma palpebrarum.
